Loading organizations...
§ Private Profile · Daejeon, Taejon-jikhalsi, South Korea
Biotech developing engineered exosome therapeutics for inflammatory, autoimmune, CNS, oncology, immune, and renal diseases.
ILIAS Biologics, based in Daejeon, South Korea with a US office in Gilroy, CA, develops engineered exosome therapeutics for inflammatory, autoimmune, CNS, oncology, immune, and renal diseases. The company leverages proprietary platforms such as EXPLOR®, Exo-Target®, and Pure-Exo® for protein loading, surface targeting, and scalable manufacturing of exosomes. Its lead candidate, ILB-202, entered a Phase 1 clinical trial in Australia for cardiac surgery-associated acute kidney injury, marking it as the first Korean exosome therapeutic to enter a global clinical trial. With over 30 employees, ILIAS Biologics has secured more than $17 million in its 2018 Series A funding round, subsequently raising Series B in 2020 and Series C in 2022. The leadership team includes Chief Development Officer Cheolhyoung Park, PhD, and Chief Scientific Officer Deok-Jin Jang, PhD. ILIAS Biologics was founded in 2015 by Chulhee Choi, MD, PhD.
ILIAS Biologics has raised $20.6M across 1 funding round.
ILIAS Biologics has raised $20.6M in total across 1 funding round.
ILIAS Biologics has raised $20.6M across 1 funding round. Most recently, it raised $20.6M Series B in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2020 | $20.6M Series B | — | Asset ONE, Daedeok Venture Partners, Daishin Private Equity, DEV Sisters Ventures, Genie Asset Management, Hanyang Securities/yeolim Partners, HB Investment, Kiwoom Securities, Meritz Securities, Timefolio Asset Management | Announced |
ILIAS Biologics has raised $20.6M in total across 1 funding round.
ILIAS Biologics's investors include Asset One, Daedeok Venture Partners, Daishin Private Equity, Dev Sisters Ventures, Genie Asset Management, Hanyang Securities/Yeolim Partners, HB Investment, Kiwoom Securities, Meritz Securities, Timefolio Asset Management.